Resistance to first-generation TRK inhibitor therapy in NTRK fusion-positive adult and pediatric cancers conditions next-generation TRK inhibitor activity: a phase I study of selitrectinib
Abstract Purpose: Next-generation TRK inhibitor benefit in NTRK fusion-positive cancers has not been prospectively characterized in relation to the wide variety of first-generation TRK inhibitor resistance mechanisms. Data from the global, multicenter, adult and pediatric phase 1 basket trial of selitrectinib (NCT03215511) was thus analyzed. Experimental design: Eligible patients were aged ≥1 month with any type of solid tumors harboring NTRK fusions. Patients had previously received a TRK inhibitor and progressed on or after, or become intolerant of, this prior therapy, with resistance determined by pre-selitrectinib tumor/plasma sample sequencing. Patients were enrolled in a 3+3 dose-escalation design (aged ≥12 years) or a rolling-6 design (aged <12 years). The primary objective was to determine the maximum-tolerated dose and/or recommended dose for further study. Secondary endpoints included safety, overall response rate (ORR), and pharmacokinetics. Results: Most patients were larotrectinib (70%) or entrectinib (30%) pretreated. Pre-selitrectinib NTRK resistance mutation(s) were identified in 46% of patients. Selitrectinib ORR was highest in on-target only resistance (45%, 95% CI 17–77). Responses were achieved only in solvent-front (e.g., NTRK1 G595R, NTRK3 G623X) and gatekeeper (e.g., NTRK1 F589L, NTRK3 F617X) mutant cancers. MAPK/PI3K pathway alteration-containing cancers did not respond to selitrectinib. Median progression-free survival was worse in MAPK/PI3K alteration-containing cancers (1.8 months, 95% CI 1.6–3.5) than cancers without these alterations (7.0 months, 95% CI 5.3–9.1). Conclusion: Selitrectinib demonstrated antitumor activity after prior TRK inhibition, but this varied according to the resistance mechanism. Thus, molecular characterization of resistance may help inform clinical use of next-generation TRK inhibitors.
Authors
- Shivaani Kummar (ORCID: https://orcid.org/0000-0001-6906-1627)
- Noah C. Federman (ORCID: https://orcid.org/0000-0002-2627-6772)
- Martin Højgaard (ORCID: https://orcid.org/0000-0003-1850-535X)
- Víctor Moreno (ORCID: https://orcid.org/0000-0001-6099-4236)
- Esther A. De La Cuesta (ORCID: https://orcid.org/0000-0001-7072-1493)
- David S. Hong (ORCID: https://orcid.org/0000-0001-8721-1609)
- Ahn Eugene
- Elena Garralda (ORCID: https://orcid.org/0000-0002-4412-7842)
- Alexander Edward Dela Cruz Drilon (ORCID: https://orcid.org/0000-0001-6806-9061)
- Theodore Willis Laetsch (ORCID: https://orcid.org/0000-0002-8497-3138)
- Jessica J. Lin (ORCID: https://orcid.org/0000-0001-7373-3916)
- Konstantin Lang
- Chunlin Chen
- Rong Du (ORCID: https://orcid.org/0009-0000-0072-6926)
Institutions
- Hebron University (PS)
- Memorial Sloan Kettering Cancer Center (US)
- Children's Hospital of Philadelphia (US)
- The University of Texas MD Anderson Cancer Center (US)
- Bayer (United States) (US)
- University of California, Los Angeles (US)
- Oregon Health & Science University (US)
- Loyola University Chicago (US)
- Rigshospitalet (DK)
- Vall d'Hebron Institut de Recerca (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Mass General Brigham (US)
- Bayer (Germany) (DE)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1158/2767-9764.crc-26-0383
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00